Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

NICE green light for Cablivi in rare blood-clotting disorder

The UK’s National Institute for Health and Care Excellence (NICE) has given a green light to Sanofi’s Cablivi for acquired thrombotic thrombocytopenic purpura (aTTP) – a rare and potentially life-threatening blood clotting disorder.

The new NICE guidance applies to the treatment of an acute episode of aTTP in adults and in young people aged 12 years and over who weigh at least 40kg.

The decision to recommend Cablivi (caplacizumab) is based on data from the phase III HERCULES study, which compared the efficacy and safety of Cablivi compared to placebo, plus standard of care, in 145 patients with aTTP.

The results from that study showed that Cablivi in addition to standard of care, when compared to placebo, decreased the median time for platelets to recover to normal levels and reduced the risk of death, as well as recurrence of TTP or formation of major clots in blood vessels.

Although Cablivi is an ultra-rare disease treatment and was initially set to be considered with NICE’s Highly Specialised Technology (HST) process, it was finally assessed under the Single Technology Appraisal (STA) process.

“We are pleased that NHS patients will be granted access to this treatment in the future. It has, however, been a long-awaited result, delaying access for those most in need, and one which could have been simplified if Cablivi had been assessed under the Highly Specialised Technology process,” said Deborah Lough, head of Rare Blood Disorders, UK & Ireland, Sanofi Genzyme.

“Throughout this time, we have remained committed to aTTP patients through the free supply scheme we have had in place for over two years. We now hope that the forthcoming NICE Methods Review and Innovative Drugs Fund consultation will fix the ongoing barriers for patients,” she added.

13th November 2020


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies